

Compose

- Inbox 281
- Starred
- Snoozed
- Sent
- Drafts 39
- More

- Meet
- New meeting
  - Join a meeting

- Hangouts
- Yudi Her



No recent chats  
Start a new one

Enable desktop notifications for



21 of 22

### Article submission received Inbox x



research@f1000.com  
to me

Sun, 19 Apr 2020, 14:12

Dear Yudi Her

Thank you for submitting your manuscript:

**Human Umbilical Cord Blood-Mesenchymal Stem Cells derived Secretome and its Combination with Atorvastatin Enhanced Endothelial Progenitor Cells Proliferation and Migration**  
Yudi Her Oktaviono *et al.*

**Funders:** you have stated during the submission process that this work has been funded by:  
Prodia Education and Research Institute

**WHAT WE DO NEXT**

**Before accepting your article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing your article:** if we **accept** your article, we will be in touch in the next two or three working days with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.

**WHAT YOU NEED TO DO NEXT**

Before doing anything else, we need you to suggest **at least 5** suitable reviewers to peer review your manuscript following publication (in accordance with our [publishing model](#)), should it be **accepted**. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your [Suggest Reviewers](#) page for this article. You can also access this page via the article's record at [My Research >> Submissions](#).

Please quote the article number 23547 in any correspondence.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. F1000 Research Limited does not **accept** liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322926, Registered Office Middlesex House, 34-42 Cleveland Street, London W1T 4LB.

Do not delete (filing code): F1KR00CDE F1R-VER25984-A (end code)

Reply Forward

Gmail. OK No thanks X

Compose

- Inbox 281
- Starred
- Snoozed
- Sent
- Drafts 39
- More

Meet

- New meeting
- Join a meeting

Hangouts

- Yudi Her +



Your article 23547 is now **accepted**



research@f1000.com  
to me

Wed, 13 May 2020, 18:19

Dear Yudi Her

Human umbilical cord blood-mesenchymal stem cell-derived secretome in combination with atorvastatin enhances endothelial progenitor cells proliferation and migration  
Oktaviono YH, Hutomo SA, Al-Farabi MJ, Chouw A and Sandra F

**PLEASE NOTE:** due to an increase in submissions regarding COVID-19, it may take longer for us to send you a PDF proof of your article. Please **accept** our apologies, and rest assured our editorial team will be in touch as soon as possible.

We have now **accepted** your article for publication in F1000Research. It will be sent to the typesetters and a member of the Production team will send you a proof in due course.

One of our editorial team will be assisting you with the peer review process of your article, and will be your main contact once the article is published.

Best wishes,

Jonathan  
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not **accept** liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER25984-A (end code)

Reply

Forward



No recent chats  
[Start a new one](#)

Enable desktop notifications for Gmail.